(Q33950898)

30 July 2017

title

Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine (English)

1 reference

30 July 2017

0 references

1 reference

Anne Prenzler

1

1 reference

30 July 2017

Linnette Yen

series ordinal

2

1 reference

30 July 2017

Thomas Mittendorf

series ordinal

3

1 reference

30 July 2017

J-Matthias von der Schulenburg

series ordinal

4

1 reference

30 July 2017

publication date

5 July 2011

1 reference

BMC Health Services Research

30 July 2017

published in

1 reference

30 July 2017

volume

11

1 reference

30 July 2017

page(s)

157

1 reference

Creative Commons Attribution 2.0 Generic

30 July 2017

copyright license

start time

5 July 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

exact match

https://scigraph.springernature.com/pub.10.1186/1472-6963-11-157

0 references

cites work

Inflammatory bowel disease: clinical aspects and established and evolving therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146407

Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146407

Systematic review: adherence issues in the treatment of ulcerative colitis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146407

5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146407

Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146407

Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146407

The risk of colorectal cancer in ulcerative colitis: a meta-analysis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146407

Epidemiology of inflammatory bowel disease in the county of Tübingen (West Germany).

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146407

Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146407

The direct and indirect cost burden of Crohn's disease and ulcerative colitis

5 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-11-157

A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-11-157

Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-11-157

An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-11-157

Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-11-157

[Costs of ulcerative colitis within the German Statutory Health Insurance].

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-11-157

[Epidemiologic aspects of Crohn regional enterocolitis and ulcerative colitis in Marburg/Lahn (West Germany) between 1962 and 1975]

21 January 2018

1 reference

12 December 2020

Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study

1 reference

12 December 2020

Course of ulcerative colitis: analysis of changes in disease activity over years

1 reference

12 December 2020

Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis

1 reference

12 December 2020

Once-daily, high-concentration MMX mesalamine in active ulcerative colitis

1 reference

12 December 2020

[Appraisal of resource use in the German health-care system from the perspective of the statutory health insurance]

1 reference

12 December 2020

German recommendations on health economic evaluation: third and updated version of the Hanover Consensus

1 reference

12 December 2020

Identifiers

DOI

10.1186/1472-6963-11-157

1 reference

Dimensions Publication ID

30 July 2017

0 references

1 reference

30 July 2017

1 reference